Findings

What do systematic reviews say?

4,736 questions · 15,265 findings · 1,163 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,871 · 25.4%GRADE not reported 810 · 5.3%Very low 4,242 · 27.8%Low 3,879 · 25.4%Moderate 1,999 · 13.1%High 464 · 3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Recombinant human growth hormone vs placebo or no intervention

Body proportions: sitting height SDS · children with X‐linked hypophosphataemia

Summary of findings ‐ recombinant growth hormone showed no clear difference in body proportions: sitting height SDS compared with placebo or no intervention (moderate certainty).

1 finding from 1 review

Recombinant growth hormone therapy for X‐linked hypophosphatemia in children 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Moderate

Recombinant human growth hormone vs placebo or no intervention

Adverse effects · children with X‐linked hypophosphataemia

1 finding from 1 review

Recombinant growth hormone therapy for X‐linked hypophosphatemia in children 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 20 participants
Low

Calf and hamstring stretching vs no intervention

Change in cramp frequency (cramps per night) (after 6 weeks) · older adults with lower limb muscle cramps

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Calf and hamstring stretching vs no intervention

Adverse events · older adults with lower limb muscle cramps

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Moderate

Calf and hamstring stretching vs no intervention

Change in cramp severity (0 to 10 VAS; higher = worse pain) (after 6 weeks) · older adults with lower limb muscle cramps

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Low

Calf and hamstring stretching vs no intervention

Proportion of participants experiencing cramps · older adults with lower limb muscle cramps

The review found no eligible studies for this question.

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Calf and hamstring stretching vs no intervention

Health‐related quality of life · older adults with lower limb muscle cramps

The review found no eligible studies for this question.

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Calf and hamstring stretching vs no intervention

Quality of sleep · older adults with lower limb muscle cramps

The review found no eligible studies for this question.

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Calf and hamstring stretching vs no intervention

Activities of daily living · older adults with lower limb muscle cramps

The review found no eligible studies for this question.

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dopamine agonist vs placebo or no intervention

Moderate or severe OHSS · women undergoing assisted reproduction

Dopamine agonist probably leads to lower incidence of moderate or severe OHSS compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 0.32 [0.23, 0.44]
10 studies · 1202 participants
Moderate

Dopamine agonist vs other active intervention

Moderate or severe OHSS · women undergoing assisted reproduction

It is very uncertain whether dopamine agonist changes incidence of moderate or severe OHSS compared with other active intervention (very low certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 0.21 [0.12, 0.38]
3 studies · 296 participants
Very low

Dopamine agonist vs other active intervention

Live birth rate · women undergoing assisted reproduction

Dopamine agonist showed no clear difference in live birth rate compared with other active intervention (low certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 1.08 [0.73, 1.59]
2 studies · 430 participants
Low

Dopamine agonist vs other active intervention

Clinical pregnancy rate · women undergoing assisted reproduction

Dopamine agonist showed no clear difference in clinical pregnancy rate compared with other active intervention (moderate certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 1.04 [0.81, 1.33]
7 studies · 1060 participants
Moderate

Dopamine agonist vs other active intervention

Multiple pregnancy rate · women undergoing assisted reproduction

Dopamine agonist showed no clear difference in multiple pregnancy rate compared with other active intervention (low certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 0.87 [0.47, 1.59]
3 studies · 400 participants
Low

Dopamine agonist vs other active intervention

Miscarriage · women undergoing assisted reproduction

Dopamine agonist showed no clear difference in miscarriage rate compared with other active intervention (low certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 0.66 [0.35, 1.25]
4 studies · 630 participants
Low

Dopamine agonist vs other active intervention

Any other adverse events · women undergoing assisted reproduction

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 170 participants
GRADE not reported

Dopamine agonist vs placebo or no intervention

Live birth rate · women undergoing assisted reproduction

Dopamine agonist showed no clear difference in live birth rate compared with placebo/no intervention (low certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 0.96 [0.6, 1.55]
3 studies · 362 participants
Low

Dopamine agonist vs placebo or no intervention

Clinical pregnancy rate · women undergoing assisted reproduction

Dopamine agonist showed no clear difference in clinical pregnancy rate compared with placebo/no intervention (low certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 0.92 [0.63, 1.37]
5 studies · 530 participants
Low

Dopamine agonist vs placebo or no intervention

Multiple pregnancy rate · women undergoing assisted reproduction

It is very uncertain whether dopamine agonist changes multiple pregnancy rate compared with placebo/no intervention (very low certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 0.32 [0.01, 8.26]
1 study · 40 participants
Very low

Dopamine agonist vs placebo or no intervention

Miscarriage · women undergoing assisted reproduction

Dopamine agonist showed no clear difference in miscarriage rate compared with placebo/no intervention (low certainty).

1 finding from 1 review

Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
OR 0.66 [0.19, 2.28]
2 studies · 168 participants
Low